[211At]YF2 / D&D Pharmatech - LARVOL DELTA

D and D Pharmatech announced on February 19 that the first clinical results for [211At]YF2, a next-generation alpha radiotherapeutic for the treatment of prostate cancer based on astatine-211 and currently being developed by its U.S. affiliate G Alpha, have been published in the international journal European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). (The Asia Business Daily) - "According to D and D Pharmatech, [211At]YF2 demonstrated its potential as a next-generation radiopharmaceutical by clearly targeting metastatic lesions, which are a major cause of cancer-related death, while minimizing damage to normal organs....In SPECT/CT analysis, [211At]YF2 was observed to accumulate in metastatic lesions within one hour after administration. Accumulation in the salivary glands was up to ten times lower than that of existing therapies under development. No grade 3 or higher severe adverse events were reported in participating patients."

Clinical data • Castration-Resistant Prostate Cancer